Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




May
03
Today In Oncology
FDA Approves Vepdegestrant for ER-HER2 ESR1 Advanced Breast Cancer
Melanoma Gut Microbiome May Help Predict Recurrence After Immunotherapy
Association of Body Size and Bladder Cancer Risk
5-Year Follow-Up From AUGMENT Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
Can PFAS Exposure Raise ALL Risk?
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo